Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Gains from Sales and Divestitures: 2018-2023

Historic Gains from Sales and Divestitures for Dianthus Therapeutics (DNTH) over the last 3 years, with Dec 2023 value amounting to $6,495.

  • Dianthus Therapeutics' Gains from Sales and Divestitures fell 91.51% to $6,495 in Q4 2023 from the same period last year, while for Dec 2023 it was $6,495, marking a year-over-year decrease of 91.51%. This contributed to the annual value of $6,495 for FY2023, which is 91.51% down from last year.
  • Latest data reveals that Dianthus Therapeutics reported Gains from Sales and Divestitures of $6,495 as of FY2023, which was down 91.51% from $76,539 recorded in FY2022.
  • In the past 5 years, Dianthus Therapeutics' Gains from Sales and Divestitures ranged from a high of $76,539 in FY2022 and a low of $6,495 during FY2023.
  • For the 2-year period, Dianthus Therapeutics' Gains from Sales and Divestitures averaged around $41,517, with its median value being $41,517 (2022).
  • Data for Dianthus Therapeutics' Gains from Sales and Divestitures shows a maximum YoY plummeted of 91.51% (in 2023) over the last 5 years.
  • Dianthus Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $76,539 in 2022, then plummeted by 91.51% to $6,495 in 2023.